Ipratropium
Mostrando 1-12 de 64 artigos, teses e dissertações.
-
1. A randomized clinical trial on inhaled ciclesonide for managing acute asthma in the emergency room
ABSTRACT BACKGROUND: Use of inhaled corticosteroids for managing acute asthma exacerbations has been tested since the 1990s. OBJECTIVE: To compare high doses of inhaled ciclesonide with systemic hydrocortisone for managing acute asthma exacerbations in the emergency department. DESIGN AND SETTING: Double-blind, randomized clinical trial in the public heal
Sao Paulo Medical Journal. Publicado em: 2022
-
2. The exercise of bronchodilatadors and oxygen alone and in combination on exercise performance in COPD / "Efeito da oxigenoterapia e dos broncodilatadores no desempenho físico de pacientes com DPOC"
Our objective was assess the effect of oxygen (O2) and bronchodilator (BD) on reduce exertional breathlessness and improve exercise tolerance in patients with COPD. Nebulization of 5 mg of salbutamol plus 500 ug ipratropium bromide followed by a six-minute walking test while breathing O2 were studient in 28 patients with severe COPD, breathless on exertion a
Publicado em: 2006
-
3. Efeito da interrupÃÃo abrupta do tratamento crÃnico com brometo de ipratrÃpio na resposta contrÃtil de traquÃias isoladas de ratos / Effect of ipratropium bromide abrupt withdrawal, after chronic treatment, in contractile response of isolated rat tracheas
Visando estudar os efeitos da retirada abrupta apÃs o tratamento crÃnico com brometo de ipratrÃpio (BI) ratos machos pesando 200-250 g no inÃcio dos experimentos, foram introduzidos em uma caixa de acrÃlico e submetidos durante 7 minutos à inalaÃÃo de brometo de ipratrÃpio (600ÂM). Este procedimento se repetiu a cada quatro horas durante um perÃod
Publicado em: 2004
-
4. Is nocturnal asthma caused by changes in airway cholinergic activity?
A randomised, double blind, placebo controlled crossover trial of high dose nebulised ipratropium was carried out in 10 asthmatic patients with documented nocturnal bronchoconstriction. Patients received nebulised saline or ipratropium 1 mg at 10 pm and 2 am on two nights. Absolute peak flow (PEF) rates were higher throughout the night after the patients had
-
5. Bronchodilatation and the site of airway resistance in severe chronic bronchitis.
Twenty-one patients with severe chronic bronchitis and emphysema (FEV1 less than 1 1) inhaled 80 microgram of the atropine-like agent ipratropium or placebo in a double-blind study and three hours later inhaled 200 microgram salbutamol. After 80 microgram ipratropium, mean FEV1 was significantly greater than after 200 microgram salbutamol (P less than 0.025)
-
6. Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation.
The effect of adding nebulised ipratropium bromide to bronchodilator treatment was studied in 20 patients with severe chronic airflow limitation. Maintenance theophylline with or without a steroid preparation was continued and comparison made between placebo, nebulised salbutamol, and a combination of nebulised salbutamol and ipratropium. Although the mean F
-
7. Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis.
The bronchodilating responses to 400 micrograms salbutamol and 80 micrograms ipratropium bromide were studied in 188 patients with chronic bronchitis (n = 113) or asthma (n = 75) and mild to moderate airflow obstruction (forced expiratory volume in one second (FEV1) above 50% but below 2 SD of predicted value) in a crossover study on two days a week apart. B
-
8. Comparison of the efficacy of preservative free ipratropium bromide and Atrovent nebuliser solution.
The paradoxical bronchoconstriction observed with commercially available isotonic ipratropium bromide nebuliser solution (Atrovent) in patients with asthma results from an adverse reaction to the preservatives, benzalkonium chloride and ethylenediaminetetra-acetic acid (EDTA). The airway response to inhaled Atrovent and preservative free ipratropium bromide
-
9. Ipratropium bromide treatment of experimental rhinovirus infection.
The importance of parasympathetic-cholinergic mechanisms in the production of common cold symptoms is not clear. The quaternary ammonium anticholinergic antagonist ipratropium bromide was intranasally administered under double-blind, randomized, placebo-controlled conditions to assess its tolerance and efficacy in reducing nasal hypersecretion in adult volun
-
10. Influence of age on response to ipratropium and salbutamol in asthma.
We studied the differential response to inhaled salbutamol and ipratropium of 29 asthmatic patients, 18 intrinsic, 11 extrinsic, using peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV1), and forced vital capacity (FVC). Thirty minutes after a theoretically maximally bronchodilating dose of salbutamol (400 microgram) or ipratropiu
-
11. Bronchial responsiveness to hyperventilation in children with asthma: inhibition by ipratropium bromide.
Isocapnic hyperventilation dose response curves were constructed for 11 asthmatic children before and after pretreatment with placebo or ipratropium bromide, 40-1500 micrograms given by inhalation, on three separate days. The response before and after placebo was highly reproducible (within subject coefficient of variation 7.5%, 18%, and 22% for intervals of
-
12. Sodium cromoglycate and ipratropium bromide in exercise-induced asthma.
In thirteen patients with extrinsic asthma the effects of placebo, sodium cromoglycate, ipratropium bromide, and ipratropium bromide plus sodium cromoglycate were studied in a random double-blind fashion to assess their inhibitory action in exercise-induced asthma (EIA). Exercise testing consisted of steady state running on an inclined treadmill for up to ei